Center for Immunology and Immune Therapies

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Investigate the Implications of Loss of Gut Microbiota Diversity and Long-term Clinical Outcomes in alloHSCT Recipients

   Jacksonville, Fla.

   In this study we seek to investigate the implications of loss of gut microbiota diversity by correlating them with long-term clinical outcomes in alloHSCT recipients.

2. Will Making the HPV Vaccine Available at Mayo Clinic Express Care with Use of Electronic Point of Care Reminder Improve Overall Vaccination Rates Among an Empaneled Adolescent Population?

   Rochester, Minn.

   The purpose of this study is to determine if a medical record prompt at the time of a medical consult will help to address lapses in routine immunizations, including the HPV vaccine.

    

    

3. Study the Variations in the Humoral and Cellular Immune System in Healthy Volunteers

   Rochester, Minn.

   Study the variations in the humoral and cellular immune system over time (longitudinally over 2 years) in normal healthy volunteers.

4. A Study of Using Lorvotuzumab Mertansine in Treating Younger Patients with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

   Rochester, Minn.

   The purpose of this study is to see how well lorvotuzumab mertansine works in treating younger patients with Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), or synovial sarcoma that has returned or that does not respond to treatment. Antibody-drug conjugates, such as lorvotuzumab mertansine, are created by attaching an antibody (protein used by the body's immune system to fight foreign or diseased cells) to an anti-cancer drug. The antibody is used to recognize tumor cells so the anti-cancer drug can kill them.

5. A Study of Patients Treated for Wiskott-Aldrich Syndrome Since 1990

   Rochester, Minn.

   Wiskott - Aldrich syndrome (WAS) is a rare serious medical condition that causes problems both with the immune system and with easy bruising and bleeding. The immune abnormalities cause patients with WAS to be very susceptible to infections. Depending on the specific type of primary immune deficiency diseases, there are effective treatments, including antibiotics, cellular therapy and gene therapy, but studies of large numbers of patients are needed to determine the full range of causes, natural history, or the best methods of treatment for long term success. This multicenter study combines retrospective, prospective and cross-sectional analyses of the transplant experiences for patients with WAS who have already received Hematopoietic cell transplant (HCT) since 1990, or who will undergo HCT during the study period. The retrospective and prospective portions of the study will address the impact of a number of pre and post-transplant factors on post-transplant disease correction and ultimate benefit from HCT.  The cross-sectional portion of the study will assess the benefit of HCT 2 years post-HCT.

6. A Study to Learn More About the Relationship between Fetal DNA and the Maternal Immune System

   Rochester, Minn.

   The purpose of this study is to learn about the ability of fetal DNA to activate the immune system.

7. A Study to Better Understand How to Predict and Manage Patients Who are at High Risk for Developing Rheumatic Immune-related Adverse Events While Receiving Treatment for Melanoma

   Rochester, Minn.

   The purpose of this study is to:

   1. Understanding how to better predict and manage patients at high risk for rheumatic irAEs and tailor therapy without diminishing cancer treatment efficacy and,
   2. Further inform our understanding on the pathogenesis of classic rheumatologic diseases.
   3. Establish a repository of biological samples from patients with irAE and corresponding rheumatologic

8. A Study of Patients Treated for Chronic Granulomatous Disease Since 1995

   Rochester, Minn.

   Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone marrow transplantation has been shown to be curative. However the risks of transplantation are high and not all patients with CGD may need to undergo this high risk procedure. The purpose of this study is to determine the long term medical condition and daily functioning of patients with CGD after a transplant and if possible, compare these results to patients who do not undergo a transplant.

9. Collection of Tissue and Blood in Patients with Allergic and Immunologic Disorders

   Scottsdale/Phoenix, Ariz.

   Allergic and immunologic disorders are very common but some are very poorly understood. Numerous studies of the epidemiology, characteristics, diagnosis and treatment of these disorders are urgently needed to identify and optimally treat affected patients. Though numerous challenges impact the progress of research in this area, specimens are needed to test new hypotheses and methodologies.  We aim to create a registry and biorepository of tissue and fluid specimens for future studies.

10. SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    This phase II trial studies how well second mitochondrial-derived activator of caspases (SMAC) mimetic LCL161 alone or with cyclophosphamide works in treating patients with relapsed or refractory multiple myeloma. Biological therapies, such as SMAC mimetic LCL161, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving SMAC mimetic LCL161 alone or with cyclophosphamide is more effective in treating multiple myeloma.